Abstract:
Background This study aimed to compare the clinical outcomes of a heparin surface-modified (HSM) hydrophobic acrylic foldable intraocular lens (IOL) (CT LUCIA 601PY) and non-heparin-modified hydrophobic acrylic foldable IOL (AcrySof IQ SN60WF) in diabetic patients undergoing phacoemulsification. Methodology This randomized, single-surgeon, double-masked controlled trial was conducted at Dr. Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi. In this randomized controlled trial, 100 eyes of 100 diabetic patients with or without mild-to-moderate diabetic retinopathy were enrolled (HSM IOL, n = 50; non-HSM IOL, n = 50). Outcome measures were aqueous flare, visual acuity, and anterior chamber depth (ACD). These were measured preoperatively as well as one day, one week, one month, three months, six months, and one year postoperatively. Results The HSM IOL group had significantly lower anterior chamber aqueous flare values (photon count/ms) than the non-HSM IOL group on postoperative day one (9.97 ± 5.2 vs. 17.56 ± 11.3, p < 0.001), postoperative week one (11.47 ± 7.78 vs. 17.06 ± 9.4, p = 0.02), and postoperative month three (7.7 ± 4.1 vs. 12.5 ± 5.6, p = 0.004) of phacoemulsification. The corrected distance visual acuity (CDVA) was significantly better in the HSM IOL group on postoperative day one (uncorrected distance visual acuity: p = 0.022; CDVA; p = 0.005), but there was no significant difference at any other follow-ups. ACD was significantly longer in the HSM IOL group at all follow-ups. Conclusions The implantation of HSM IOL resulted in significantly lower inflammatory reactions in the early postoperative period in diabetics.
摘要:
背景这项研究旨在比较肝素表面修饰(HSM)疏水性丙烯酸可折叠人工晶状体(IOL)(CTLUCIA601PY)和非肝素修饰的疏水性丙烯酸可折叠IOL(AcrySofIQSN60WF)在接受超声乳化术的糖尿病患者中的临床结果。方法学随机,单外科医生,双盲对照试验在RajendraPrasad博士眼科科学中心进行,全印度医学科学研究所,新德里。在这项随机对照试验中,纳入100例有或没有轻度至中度糖尿病视网膜病变的糖尿病患者的100只眼(HSMIOL,n=50;非HSMIOL,n=50)。结果措施是含水耀斑,视敏度,和前房深度(ACD)。这些都是术前和一天测量的,一个星期,一个月,三个月,六个月,术后一年。结果术后第一天,HSMIOL组前房房水闪烁值(光子计数/ms)明显低于非HSMIOL组(9.97±5.2vs.17.56±11.3,p<0.001),术后第1周(11.47±7.78vs.17.06±9.4,p=0.02),术后3个月(7.7±4.1vs.12.5±5.6,p=0.004)的白内障超声乳化术。术后第一天,HSMIOL组的矫正视力(CDVA)明显更好(未矫正视力:p=0.022;CDVA;p=0.005),但在其他随访中没有显著差异.在所有随访中,HSMIOL组的ACD明显更长。结论糖尿病患者术后早期HSMIOL植入可显著降低炎症反应。